⌕
Lilly(Eli) · LLY · NYSE
Tenet 49 · Mixed
Compare
$1,415.55−1.13%At closeTenet 49 · Mixed
$1,415.55−16.12 (−1.13%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$1,400.12−15.43 (−1.09%)
After hours: Nov 17, 2026, 7:58 PM ET

Lilly(Eli) (LLY) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Defense WorldNov 17, 2026 · 08:01 ETEARNINGS EXPECTED BY FEB 1
Eli Lilly and Company $LLY Shares Acquired by Banco Santander S.A.

Banco Santander S.A. raised its position in Eli Lilly and Company (NYSE: LLY) by 48.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 178,190…

● GuruFocusNov 16, 2026 · 12:55 ET
Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody

Eli Lilly and Co. (LLY) agreed to acquire Calytrix Bio for up to $1.5 billion in cash. The total includes an upfront payment and further payments tied to clinic…

● Zacks Investment ResearchNov 16, 2026 · 10:01 ET
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

● Defense WorldNov 15, 2026 · 11:27 ETEARNINGS EXPECTED BY FEB 1
Danske Bank A S Sells 71,588 Shares of Eli Lilly and Company $LLY

Danske Bank A S reduced its stake in Eli Lilly and Company (NYSE: LLY) by 9.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm …

● Defense WorldNov 15, 2026 · 11:27 ETEARNINGS EXPECTED BY FEB 1
2,565 Shares in Eli Lilly and Company $LLY Bought by California First Leasing Corp

California First Leasing Corp bought a new stake in Eli Lilly and Company (NYSE: LLY) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The…

● Defense WorldNov 14, 2026 · 07:23 ETEARNINGS EXPECTED BY FEB 1
Bernicke Wealth Management Ltd. Makes New $5 Million Investment in Eli Lilly and Company $LLY

Bernicke Wealth Management Ltd. purchased a new position in shares of Eli Lilly and Company (NYSE: LLY) in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm p…

● Zacks Investment ResearchNov 13, 2026 · 10:16 ET
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day

LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.…

● PRNewsWireNov 12, 2026 · 15:30 ETCOMPANY'S OWN WORDS
Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020

Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobs INDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today br…

● Schwab NetworkNov 12, 2026 · 13:00 ET
The Big 3: JNJ, LLY, AAPL

Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks including Johnson & J…

● BenzingaNov 11, 2026 · 09:56 ET
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposure a…

● PRNewsWireNov 11, 2026 · 09:45 ET
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improveme…

● Seeking AlphaNov 10, 2026 · 09:00 ET
10 Dividend Growth Stocks: November 2026

In this monthly series, I rank a selection of dividend growth stocks and present the top 10 for consideration. To rank stocks, I sort candidates by quality score. This month's top 10, led by AMAT, LRCX, LLY, and AVGO, ar…

● PRNewsWireNov 10, 2026 · 08:00 ET
Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting

After years of thinking she should be able to manage her weight on her own, Leanne shares how a conversation with her doctor led her to Foundayo, and why she encourages others to talk with their healthcare providers INDI…

● PRNewsWireNov 9, 2026 · 09:30 ET
Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss

In adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission or mild disease  Found…

● PRNewsWireNov 6, 2026 · 06:47 ETCOMPANY'S OWN WORDS
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYS…

● PRNewsWireNov 5, 2026 · 06:45 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 1
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee p…

Expected by Feb 1. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just LLY · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.